News of Note—Gardasil-Cervarix divide, flu vaccines and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Starting from this fall, students in Quebec are receiving one shot of Merck & Co.’s Gardasil 9 and then later a shot of GlaxoSmithKline’s Cervarix to protect against HPV. Experts worry the new program will not build sufficient immunity to seven of the nine strains not covered in Cervarix. The Globe and Mail article

> Italy’s health minister, Giulia Grillo, from the vaccine-skeptic party Five Star Movement, has sacked the entire board of the country’s health advisory committee. The Guardian article

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> An ongoing shortage of GlaxoSmithKline’s popular shingles vaccine, Shingrix, has caused frustration among people waiting to get it. The Boston Globe article

> About 60% of people 60 and older in the U.S. have gotten a flu shot this season, according to new data from Clover Health. UPI article

> The global vaccines market is expected to reach $57.5 billion by 2025, up from from $33.7 billion in 2018, according to a report from Meticulous Research. Release

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.